Latest news with #Adagio
Hospitality Net
27-05-2025
- Business
- Hospitality Net
Adagio Original London City East: Europe's Leading Aparthotel Brand Opens Innovative Flagship in the Heart of London
The Adagio Original London City East has just opened its doors, becoming Adagio's ninth establishment in the UK and the fourth in London for Europe's leading aparthotel brand. This new site stands out for its exceptional location, sleek modern design enhanced by exclusive artwork from a local artist, as well as several innovations, such as a new apartment furnishing concept and five coliving apartments. Offering the highest standards in hospitality, this new flagship features 132 studios and apartments, accommodating 1 to 8 guests. An ideal location, right in the heart of London Located right in the heart of London, just steps from the City and only a 5-minute walk from Aldgate East or Whitechapel tube stations, the Adagio Original London City East is perfectly situated for both business travellers and holiday makers exploring the British capital. Visitors will be able to enjoy the vibrant and multicultural atmosphere of Whitechapel, whilst also being just a ten-minute walk away from iconic landmarks such as the Tower of London, Tower Bridge, Brick Lane, and Old Spitalfields Market,. Innovative and modern, with a distinctly urban flair The Adagio Original London City East is located in a new building, with a striking design inspired by local culture, blending traditional red bricks with a clean and elegant aesthetic. The 132 studios and apartments showcase the new Adagio Original apartment concept, 'The Smart House', which offers guests the highest level of comfort. With open-plan spaces, warm hues, and multifunctional furniture, each apartment becomes a modern sanctuary - both calming and inspiring - quickly making guests feel right at home. The first introduction of 'Coliving by Adagio' in London Another distinctive feature of this new aparthotel is the inclusion of five 'Coliving by Adagio' suites. This concept has been specifically designed to accommodate groups, whether they are travelling for work, family trips, or holidays with friends. Designed to feel like a real apartment, each co-living suite consists of four independent studios, each equipped with its own bathroom and toilet, arranged around shared spaces, a fully equipped open kitchen for down time, and a welcoming shared living room. These fully furnished spaces are ideal for longer stays, thoughtfully designed to provide maximum comfort. Decor enhanced by local artwork In celebration of Whitechapel's vibrant visual and cultural spirit, the Adagio Original London City East has commissioned local artist, The Line Girl, to enhance its decor. Known for her distinctive graphic universe piece composed of black and white lines, the artist created an in- situ artwork that winds through the spaces: a large mural unfolding from the lobby to the lift and along the corridors on each floor. Her artwork travels through the hotel, creating an immersive visual journey for guests, transforming the space into a living canvas. Deeply connected to the neighbourhood, The Line Girl captures the culture and spirit of Whitechapel, whilst also creating subtle and encompassing art for guests to inhabit and admire. By integrating unique artworks into its spaces, Adagio enriches the guest experience, placing art at the heart of every stay. This approach, embraced by all new Adagio Original properties, champions an inclusive view of art: accessible, inspiring, and emotionally engaging. Hotel website
Business Wire
15-05-2025
- Business
- Business Wire
Adagio Medical Reports First Quarter 2025 Results
BUSINESS WIRE)--Adagio Medical Holdings, Inc. (Nasdaq: ADGM) ('Adagio' or 'the Company'), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced financial results for the first quarter ended March 31, 2025. Recent Business Highlights: Received Breakthrough Device Designation from the U.S. Food and Drug Administration (the 'FDA') for the vCLAS™ Cryoablation System ('vCLAS'), for the treatment of drug-refractory, recurrent, sustained monomorphic ventricular tachycardia ('VT') in patients with ischemic or non-ischemic structural heart disease. The vCLAS TM Cryoablation System is currently the subject of the FULCRUM-VT Investigational Device Exemption ('IDE') study designed to support FDA approval. The Breakthrough Device program allows for the FDA to potentially provide Adagio with priority review and interactive communication during the vCLAS TM review phase. Surpassed 50% enrollment in the FULCRUM-VT pivotal study. The study, which seeks to enroll 206 patients with ischemic and non-ischemic disease at 20 U.S. and Canadian centers, is on track for completion of patient enrollment in the second half of 2025. Adagio's Ultra-Low Temperature Cryoablation ('ULTC') and vCLAS technologies were showcased by leading electrophysiologists during multiple scientific sessions at the recent European Heart Rhythm Association (EHRA) and Heart Rhythm Society (HRS) industry meetings. Hired industry veteran Deborah Kaster, who has more than 25 years of leadership experience in the medical technology sector, as Chief Business Officer. Implemented a corporate prioritization initiative focusing all resources on the FULCRUM-VT clinical trial activities and the Company's new product design optimization program, which has been designed to advance faster innovation and iteration to meet market demands. 'This has been a defining quarter for Adagio Medical and for our progress across the company. The FDA's Breakthrough Device Designation, multiple impactful presentations at leading industry conferences, the introduction of our optimized smaller, faster next generation ULTC technology in development and the continued momentum in enrolling patients in our FULCRUM-VT trial all underscore the clinical promise and growing validation of our proprietary ULTC platform technology,' said Todd Usen, Chief Executive Officer of Adagio. 'I am so proud of the Adagio team's accomplishments as we remain resolute in our mission to transform patient treatment and outcomes with our purpose-built solution for the large, underserved population of patients suffering from ventricular tachycardia.' First Quarter 2025 Financial Results Cost of revenue was $0.3 million for the three months ended March 31, 2025, compared to $0.5 million for the three months ended March 31, 2024. Research and development expenses were $3.7 million for the three months ended March 31, 2025, compared to $3.5 million for the three months ended March 31, 2024. Selling, general and administrative expenses were $3.5 million for the three months ended March 31, 2025, compared to $4.8 million for the three months ended March 31, 2024. Net loss for the three months ended, March 31, 2025 was $7.7 million, or $(0.50) per share, compared to a net loss of $8.0 million, or $(10.28) per share, for the three months ended, March 31, 2024. Reported cash and cash equivalents of $13.0 million as of March 31, 2025. About Adagio Medical Holdings, Inc. Adagio is a medical device company focused on developing and commercializing products for the treatment of cardiac arrhythmias utilizing its novel, proprietary, catheter-based Ultra-Low Temperature Cryoablation (ULTC) technology. ULTC is designed to create large, durable lesions extending through the depth of both diseased and healthy cardiac tissue. The Company is currently focused on the treatment of ventricular tachycardia (VT) with its purpose-built vCLAS™ Cryoablation System which is CE Marked and is currently under evaluation in the Company's FULCRUM-VT U.S. IDE Pivotal Study. About FULCRUM VT FULCRUM-VT (Feasibility of Ultra-Low Temperature Cryoablation in Recurring Monomorphic Ventricular Tachycardia) is a prospective, multi-center, open-label, single-arm study, enrolling 206 patients with structural heart disease of both ischemic and non-ischemic cardiomyopathy, indicated for catheter ablation of drug refractory VT in accordance with current treatment guidelines. The results of the study will be used to apply for FDA premarket approval (PMA) for Adagio's vCLAS™ Cryoablation System, potentially leading to the broadest industry indication for purely endocardial ablation of scar-mediated VT. Adagio's vCLAS™ Cryoablation System is commercially available for the treatment of monomorphic ventricular tachycardia in Europe and select other geographies but is limited to investigational use in the United States. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as 'anticipates,' 'believes,' 'expects,' 'intends,' 'projects,' 'plans,' and 'future' or similar expressions are intended to identify forward-looking statements. Forward-looking statements include statements concerning: the potential of our vCLAS™ Cryoablation System; our research, development and regulatory plans for our product candidates, including the timing of initiating additional trials and reporting data from our trials; the regulatory pathway for our vCLAS™ Cryoablation System and the potential impacts of the Breakthrough Device Designation; the potential for our product candidates to receive regulatory approval from the FDA or equivalent foreign regulatory agencies; and our current cash resources and the impacts of our corporate prioritization initiative and realignment of resources. Forward-looking statements are based on management's current expectations and are subject to various risks and uncertainties that could cause actual results to differ materially and adversely from those expressed or implied by such forward-looking statements. Accordingly, these forward-looking statements do not constitute guarantees of future performance, and you are cautioned not to place undue reliance on these forward-looking statements. Risks regarding our business are described in detail in our Securities and Exchange Commission ('SEC') filings, including in our Annual Report on Form 10-K for the full-year ended December 31, 2024, which is available on the SEC's website at Additional information will be made available in other filings that we make from time to time with the SEC. These forward-looking statements speak only as of the date hereof, and we disclaim any obligation to update these statements except as may be required by law. Condensed Statements of Operations Three Months Ended March 31 2025 2024 Revenue $ — $ 26 Cost of revenue 253 542 Research and development 3,659 3,469 Selling, general, and administrative 3,485 4,830 Total cost of revenue and operating expenses 7,397 8,841 Loss from operations (7,397) (8,815) Other (income) expenses: Convertible notes fair value adjustment 190 1,673 Warrant liabilities fair value adjustment 38 (80) Interest expense (662) (754) Interest income 164 1 Other income (expense), net (46) (43) Total other income, net (316) 797 Net loss $ (7,713) $ (8,018) Basic net loss per share $ (0.50) $ (10.28) Diluted net loss per share $ (0.51) $ (10.28) Weighted-average shares outstanding, basic and diluted 15,375,521 779,908 Expand
Scroll.in
12-05-2025
- Entertainment
- Scroll.in
Start the week with a film: In ‘Last Night of Amore', the wages of temptation
Franco Amore is getting ready to quit the Milan police force after a 35-year stint. He has his retirement speech ready. He even has a post-retirement job waiting for him. What could go wrong? The timing, for one. Last Night of Amore (2023) is all about bad timing – the future boss who wants Franco to carry out a task even before he has officially ceased to be a cop, the wrong moves made during a routine drop, Franco's own haste to give his family the life he has never been able to afford. Andrea Di Stefano's stylish Italian thriller is out on Prime Video and can also be rented from BookMyShow Stream. The 124-minute film jumbles up its timeline, moving between a tense situation that unfolds over a single night and the events that lead to the standoff. Last Night of Amore pays visual homage to Stefano Sollima's moody neo-noir dramas about corruption and moral choices (among these, Adagio is available on Netflix). In the opening sequence of Last Night of Amore, cameras glide over Milan, eventually moving downwards into Franco's apartment, where his wife Viviana is waiting for him. The pursuit of the high life is what gets Franco into trouble. He has been running a side hustle by driving around his acquaintance Cosimo. When Cosimo proposes an assignment for the Chinese businessman Zhang, Franco signs up along with his colleague Dino (Francesco Di Leva). Franco's moment of truth – the realisation that he stands to lose his carefully built-up credibility – is incredibly shot and edited. Di Stefano's examination of the wages of temptation has a raft of sharp performances, especially by Linda Caridi as Franco's supportive spouse. Such films usually relegate female characters to the sidelines, but Caridi's Viviana proves indispensable to the plotting. Renowned Italian actor Pierfrancesco Favino, a veteran of crime thrillers, is terrific in the lead role. Favino, who also stars in Adagio, memorably portrays Franco's watchful ways and his fortitude when his luck turns rotten. The night is indeed long for Franco Amore, but it doesn't feel so in Pierfrancesco Favino's company. Play
Yahoo
21-03-2025
- Business
- Yahoo
Everything we know about the latest 18-story condo project proposed for downtown Sarasota
The Adagio, another towering residential project in Sarasota's growing portfolio, is in the development pipeline for downtown. Here's what we know about it: The Adagio proposes 167 residential units and commercial space across two towers, the first stretching 18 stories and the second reaching nine stories. The development would also include 457 parking spaces dispersed throughout basement and lower-level parking areas. The project's residences are proposed as a combination of market-rate and affordable units, with 100 market-rate condos proposed the first tower and 67 affordable apartments in the second. Local development consultant Joel Freedman and DT Sarasota Development LLC, whose listed owner is Michael Hoyt, are attached to the project. The Adagio's proposed site lies at the intersection of Palm Avenue and Ringling Boulevard, just off the roundabout north of the Burns Court area. Its listed addresses of 1360 Ringling Blvd., 330 S. Pineapple Ave. and 301 and 303 S. Palm Ave. total 2.2 acres valued at $5.6 million, according to Sarasota County property records. Developer DT Sarasota Development LLC cited the the Live Local Act, a state tax credit program aimed to incentivize affordable housing, to support the development at a pre-application conference with the city of Sarasota's Development Review Committee. The act requires local governments to designate multifamily projects that meet state affordable housing criteria — at least 40% of its residential units priced as attainable — as allowable uses in areas zoned for commercial, industrial or mixed-use purposes. Attainable, in this case, is defined as 80% to 120% of the area median income — and the Adagio proposes attainable units at 120%. Sarasota County's area median household income is $77,705, according to county data. Live Local also stipulates that local governments must allow the project to build up to the municipality's largest permissible density and up to the height of the tallest building within a mile of the proposed development. Nearby properties like The Westin and The Ritz-Carlton, each within a mile of the proposed Adagio, reach 18 stories. The project's proposed density of around 74.5 units per acre renders it both eligible for and subject to the city's downtown density bonus program, which allocates additional height and density to projects that meet affordable housing requirements. The program will allow the Adagio to build 200 units per acre if the developer designates 15% of its bonus units as attainable housing — the local definition of which includes more criteria than the state level. Sarasota's attainable housing guidelines require the developers to intersperse the affordable units among the market-rate units and for all units to share a common entrance, and the affordable units must be functionally indistinguishable from the market-rate units. The Adagio proposes its affordable units and market-rate units in two separate towers, so it will have to either adjust its site plan in a formal application to meet these local requirements or reduce its density so they're no longer held to those standards. The Adagio would add another figure to Sarasota's growing skyline, with buildings like Westin and The Ritz-Carlton already to the top of the city's height parameters and future projects like The Obsidian looking to match. More downtown development has proven a daunting prospect for some local residents like Dean Scarborough, who lives at the Sansara Condominium development on Pineapple Avenue. Scarborough told the Sarasota City Commission the Adagio's height could damage property values of smaller surrounding developments like his, and he's concerned that Live Local's height and density benefits will serve the developer without requiring enough attainable housing in return. 'The city's zoning integrity is breached,' Scarborough said during public comment at a March 3 meeting. 'Many of us bought condos in this area with the understanding that 10 stories was the maximum allowable height. Others, however, are encouraged by the Adagio's possible contribution to downtown's vibrancy and growth. Denise Kowal has owned the Historic Burns Square Boutique Hotel, now Burns Square Historic Vacation Rentals, since 1986. The building at 531 S. Pineapple Ave. is about a quarter of a mile from the proposed Adagio, meaning Kowal would be the project's close neighbor if it's approved. More: to open first Florida store in Sarasota, Bradenton area later this spring Kowal said she welcomes a compact structure like the Adagio as an alternative to urban sprawl. As the Burns Court area and Sarasota at large continue to grow, Kowal said she's hopeful that residences in the heart of downtown will mitigate surrounding traffic help bolster the city's character. 'Downtown, I believe, should be a place that people live and work and do cultural experiences,' Kowal said. 'Having more people living downtown is going to make it more vibrant, and that's what we all want.' Contact Herald-Tribune Reporter Heather Bushman at hbushman@ Follow her on Twitter @hmb_1013. This article originally appeared on Sarasota Herald-Tribune: What we know about the high-rise condo project proposed for Sarasota
Yahoo
26-01-2025
- Entertainment
- Yahoo
BBCSO/Oramo review – Kaija Saariaho's final work receives poignant UK premiere
When brain cancer claimed Finnish composer Kaija Saariaho in 2023, the classical world lost one of its most distinctive voices, a vivid orchestral painter with a palette forged in Paris's avant garde electronic music labs. Fortunately for us she worked up until the end, and her final piece, receiving its UK premiere, formed the centrepiece of Sakari Oramo's smartly conceived programme on themes of death and transcendence. The concert opened with the spook-haunted Adagio from Mahler's unfinished Tenth Symphony. Oramo's imaginatively phrased reading settled in after an initial tendency to grow too loud too soon. It was followed by a pitch-perfect account of Vaughan Williams' uplifting Toward the Unknown Region. Oramo kept the music's underlying tread intrepid – no airy-fairy mysticism for him – and the BBC Symphony Chorus responded to the composer's fluent melodies with robust tone and admirable diction. Saariaho's Hush was written for the idiosyncratic Finnish trumpeter Verneri Pohjola. The composer described each of her concertos as a portrait of its soloist, and Pohjola's reflected his jazz background and gift for extended techniques that take the instrument well beyond its traditional comfort zone. The work, which also echoes Saariaho's interest in grail legends, is a musical quest in four movements containing autobiographical elements and ending in what the composer movingly referred to as her own journey into silence. The score, parts of which Saariaho credited to the two notational assistants who helped her during her illness, is shot through with spectral fragments and wheezing, asthmatic orchestral effects. An array of tuned percussion and celesta lend a certain magical sheen. Pohjola ran the gamut, breathing and muttering through his trumpet, bending bluesy notes till they broke, and even screaming amid the vicious repetitive beat of a third movement inspired by the composer's experience of MRI scans. Related: A guide to Kaija Saariaho's music As Pohjola cried out 'hush', the final movement came to a portentous halt and a charged silence broken by a breathtaking segue into Vaughan Williams' The Lark Ascending. Oramo's warmly organic interpretation was crowned by the ethereal solo violin of BBCSO leader Igor Yuzefovich. Their valedictory yet refreshingly unsentimental account served as a poignant eulogy to Saariaho's genius.
